RecruitingNCT03418441

Central Nervous System Infections in Denmark

Danish Study Group of Infections of the Brain: A Nationwide Prospective Observational Cohort Study of All Central Nervous System Infections in Adults at Departments of Infectious Diseases in Denmark


Sponsor

Aalborg University Hospital

Enrollment

1,900 participants

Start Date

Jan 1, 2015

Study Type

OBSERVATIONAL

Conditions

Summary

The Danish Study Group of Infections of the Brain is a collaboration between all departments of infectious diseases in Denmark. The investigators aim to monitor epidemiological trends in central nervous system (CNS) infections by a prospective registration of clinical characteristics and outcome of all adult (\>17 years of age) patients with community-acquired CNS infections diagnosed and/or treated at departments of infectious diseases in Denmark since 1st of January 2015.


Eligibility

Min Age: 18 Years

Inclusion Criteria33

  • Definitions of central nervous system infections:
  • For all cases with unproven aetiologies no alternative diagnosis than CNS infection is thought more likely after completed multidisciplinary diagnostic work-up.
  • \- All patients have to have a clinical presentation consistent with non-bacterial meningitis (e.g. headache, neck stiffness, photo- or phonophobia, fever)
  • and
  • Cerebrospinal fluid leukocytes\>10 cells/ml
  • Patients with viral meningitis with undetermined pathogen have to have:
  • CSF leukocytes\> 10/mL and no other more probable diagnosis assessed by the local investigator.
  • In case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.
  • and
  • Proven bacterial aetiology (CSF or blood culture/DNA based technology or antigen tests)
  • Patients with bacterial meningitis in whom the bacteria cannot not be cultured or identified by DNA-based technologies have to have:
  • \- CSF leukocytes\> 10/mL and no other more probable diagnosis assessed by the local investigator.
  • In case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.
  • \- All patient have a clinical presentation consistent with brain abscess (e.g. headache, focal neurological deficit, mass lesion on cranial imaging)
  • and
  • \- Proven microbiological aetiology by culture/DNA-based technology from pus from brain abscess or blood or CSF
  • or
  • \- Aspiration of pus from the brain abscess
  • or
  • \- Response to antimicrobial treatment
  • or
  • \- Tumour ruled out
  • or
  • \- Tumour thought less probable than abscess on MRI using diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) sequences.
  • \- A clinical presentation consistent with neuroborreliosis (e.g. radiculopathy)
  • and
  • \- CSF pleocytosis\>10 leukocytes/mL
  • and
  • \- Positive intrathecal B.burgdorferi antibody production index.
  • and either
  • \- Positive syphilis serology in serum combined with CSF leukocytes\>10/mL
  • or
  • \- CSF syphilis antibodies.

Exclusion Criteria1

  • \- We exclude cases of proven or suspected autoimmune encephalitis.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERCommunity-acquired CNS infections

Prospective observational registration of clinical characteristics and outcome


Locations(8)

Department of Infectious Diseases, Aalborg University Hospital

Aalborg, Denmark

Department of Infectious Diseases, Aarhus University Hospital Skejby

Aarhus, Denmark

Department of Infectious Diseases, Rigshospitalet

Copenhagen, Denmark

Herlev-Gentofte Hospital

Copenhagen, Denmark

Department of Pulmonary and Infectious Diseases, Nordsjællands Hospital Hillerød

Hillerød, Denmark

Department of Infectious Diseases, Hvidovre Hospital

Hvidovre, Denmark

Department of Infectious Diseases, Odense University Hospital

Odense, Denmark

Department of Pulmonary and Infectious Diseases, Sjællands University Hospital Roskilde

Roskilde, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03418441


Related Trials